Selected article for: "action mechanism and logical step"
Author: Primorac, Dragan; Čemerin, Martin; Matišić, Vid; Molnar, Vilim; Strbad, Marko; Girandon, Lenart; Zenić, Lucija; Knežević, Miomir; Minger, Stephen; Polančec, Denis
Title: Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment
  • Cord-id: glhukxw2
  • Document date: 2021_9_16
    • ID: glhukxw2
    Snippet: The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indication
    Document: The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID-19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.

    Search related documents:
    Co phrase search for related documents
    • abnormal chest and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abnormal chest imaging and acute ards respiratory distress syndrome: 1
    • abnormal chest imaging and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive innate immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adhesion molecule chemokine: 1, 2
    • acute respiratory syndrome and administration preferred route: 1, 2
    • acute respiratory syndrome and long hospital stay: 1, 2, 3
    • adaptive innate and adhesion molecule: 1, 2, 3, 4, 5
    • adaptive innate immune response and adhesion molecule: 1